119 related articles for article (PubMed ID: 26474971)
1. A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.
Pongor L; Kormos M; Hatzis C; Pusztai L; Szabó A; Győrffy B
Genome Med; 2015 Oct; 7():104. PubMed ID: 26474971
[TBL] [Abstract][Full Text] [Related]
2. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
3. Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing.
Hernan I; Borràs E; de Sousa Dias M; Gamundi MJ; Mañé B; Llort G; Agúndez JA; Blanca M; Carballo M
J Mol Diagn; 2012; 14(3):286-93. PubMed ID: 22426013
[TBL] [Abstract][Full Text] [Related]
4. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
5. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
[TBL] [Abstract][Full Text] [Related]
6. Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer.
Ozcelik H; Shi X; Chang MC; Tram E; Vlasschaert M; Di Nicola N; Kiselova A; Yee D; Goldman A; Dowar M; Sukhu B; Kandel R; Siminovitch K
J Mol Diagn; 2012 Sep; 14(5):467-75. PubMed ID: 22874498
[TBL] [Abstract][Full Text] [Related]
7. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of copy number variation by Illumina next generation sequencing is comparable in performance to oligonucleotide array comparative genomic hybridisation.
Hayes JL; Tzika A; Thygesen H; Berri S; Wood HM; Hewitt S; Pendlebury M; Coates A; Willoughby L; Watson CM; Rabbitts P; Roberts P; Taylor GR
Genomics; 2013 Sep; 102(3):174-81. PubMed ID: 23598253
[TBL] [Abstract][Full Text] [Related]
9. muTarget: A platform linking gene expression changes and mutation status in solid tumors.
Nagy Á; Győrffy B
Int J Cancer; 2021 Jan; 148(2):502-511. PubMed ID: 32875562
[TBL] [Abstract][Full Text] [Related]
10. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities for next-generation sequencing in companion diagnostics.
Lin E; Chien J; Ong FS; Fan JB
Expert Rev Mol Diagn; 2015 Feb; 15(2):193-209. PubMed ID: 25249308
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.
Roukos DH
Pharmacogenomics J; 2011 Apr; 11(2):81-92. PubMed ID: 20975737
[TBL] [Abstract][Full Text] [Related]
13. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
14. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
Chen W; Salto-Tellez M; Palanisamy N; Ganesan K; Hou Q; Tan LK; Sii LH; Ito K; Tan B; Wu J; Tay A; Tan KC; Ang E; Tan BK; Tan PH; Ito Y; Tan P
Genes Chromosomes Cancer; 2007 Mar; 46(3):288-301. PubMed ID: 17171680
[TBL] [Abstract][Full Text] [Related]
15. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Next-Generation Sequencing Assay for BRCA1 and BRCA2 Variants for the Clinical Laboratory.
Strom CM; Rivera S; Elzinga C; Angeloni T; Rosenthal SH; Goos-Root D; Siaw M; Platt J; Braastadt C; Cheng L; Ross D; Sun W
PLoS One; 2015; 10(8):e0136419. PubMed ID: 26295337
[TBL] [Abstract][Full Text] [Related]
17. Prediction of breast cancer prognosis by gene expression profile of TP53 status.
Takahashi S; Moriya T; Ishida T; Shibata H; Sasano H; Ohuchi N; Ishioka C
Cancer Sci; 2008 Feb; 99(2):324-32. PubMed ID: 18271932
[TBL] [Abstract][Full Text] [Related]
18. Clinical validation of targeted next-generation sequencing for inherited disorders.
Yohe S; Hauge A; Bunjer K; Kemmer T; Bower M; Schomaker M; Onsongo G; Wilson J; Erdmann J; Zhou Y; Deshpande A; Spears MD; Beckman K; Silverstein KA; Thyagarajan B
Arch Pathol Lab Med; 2015 Feb; 139(2):204-10. PubMed ID: 25611102
[TBL] [Abstract][Full Text] [Related]
19. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
20. What to expect from high throughput genomics in metastatic breast cancers?
Onesti CE; Vicier C; André F
Breast; 2015 Nov; 24 Suppl 2():S19-22. PubMed ID: 26238439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
